Pricing Log in Create free account
Friday 6 November 2026 Export SEPN’s income statement to Excel — free account

Septerna, Inc.

SEPN Healthcare Biotechnology

Septerna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, up 4,174.5% from fiscal 2024.

Revenue
+22,375.6%
EPS
+48.2%
Free cash flow
−9.01%

Quarter to June 2026, against a year earlier

49.54 2.19 +4.63%
Market cap
$2.2B
P/E
0.0×
Fwd P/E
−32.6×
Dividend yield
—
F-score
5/9
Altman Z
3.41
Beneish M
32.85
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Septerna, Inc. (SEPN) Net margin

Alert me on Net margin

Septerna, Inc.'s net margin over the twelve months to 30 June 2026 was −24.5%, up 81.9 percentage points from fiscal 2025 (−106.4%). That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.

Net margin, annual

Embed this chart

Annual newest first

Period Net margin Change (points)
FY2025 −106.4% 6,572.51
FY2024 −6,678.9% (7,054.38)
FY2023 375.5% —

Quarterly newest first

Period Net margin Change (points)
Jun 2026 −48.7% (16.17)
Mar 2026 −32.6% 11.96
Dec 2025 −44.5% (82.54)
Sep 2025 38.0% 20,910.29
7 more quarters

Net margin against peers

Company Net margin
AUPH Aurinia Pharmaceuticals Inc compare 97.7%
VCEL Vericel Corporation compare 10.3%
IMNM Immunome, Inc. compare 0.00%
VERA Vera Therapeutics, Inc. compare 0.00%
BHVN Biohaven Ltd. compare 0.00%
PVLA Palvella Therapeutics, Inc. compare 0.00%
LKFT Lakefront Biotherapeutics - Sponsored ADR compare −6.81%
SEPN Septerna, Inc. −24.5%
ZYME Zymeworks Inc. compare −404.0%
Biotechnology industry median 0.00%
Healthcare sector median 0.00%
Market median 1.06%

What Net margin is

Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.

Net Income Allotted to Shareholders ÷ Revenue

The full definition of Net margin →

More on SEPN